- Boston Scientific launched its Captivator EMR device for endoscopic mucosal resection
- The device is specially made for upper gastrointestinal EMR
- It provides physicians with improved visualization, control and easy passage of devices
- The device offers a 360-degree unobstructed peripheral view for a complete visualization of the diseased area
- The device includes a pathology kit to provide added convenience for endoscopists and pathologists
Boston Scientific, a manufacturer and marketer of medical devices, has recently launched its Captivator EMR device for endoscopic mucosal resection (EMR), a minimally invasive alternative to an esophagectomy. The device is specially made for upper gastrointestinal (GI) EMR and provides physicians with improved visualization, control and easy passage of devices.
“The Captivator EMR device provides improved endoscopic visualization, so the resection can be better directed to the area of interest,” said Dr. Jacques Bergman, professor of Gastrointestinal Endoscopy at University of Amsterdam, the Netherlands, and lead investigator of the global registry. “The enhanced view, along with an easy passage of accessory devices and the ability to use compatible hemostatic devices to manage potential bleeding and complications may enable a safer endoscopic resection.”
Key features of the device include:
- The device offers a 360-degree unobstructed peripheral view for a complete visualization of the diseased area when performing resections.
- Also, accessory devices such as the Boston Scientific Resolution Clip and Interject Needle can be used with the device during the procedure to manage potential complications quickly.
- The device includes a pathology kit to provide added convenience for endoscopists and pathologists.
“As a leader in GI endoscopic devices, this launch complements our existing product offering for lower GI EMR procedures and expands our portfolio into the growing upper GI EMR segment. The Captivator EMR Device provides physicians and patients with a major new option for staging and treating early esophageal neoplasia and cancer,” said David Pierce, senior vice president and president, Endoscopy, Boston Scientific.
The company also enrolled the first patient in a registry initiated to study the performance of the device for endoscopic resection of abnormal tissue growth known as early neoplasia, particularly in Barrett’s Esophagus. It will document procedural success, procedure time, quality of acquired tissue for histopathology, and procedural complications.
The registry will enroll around 300 patients at 16 clinical centers in eight countries. The study is expected to be completed in 2016.
The device is currently available in the United States, Europe, Singapore, Australia and Puerto Rico.